NewSelf GLP-1 Review 2026: Is It Worth It? Honest 5,000-Word Assessment

Quick Verdict: Who NewSelf Is (and Isn't) For

NewSelf GLP-1 offers compounded semaglutide at $99.97/month and tirzepatide at $144.49/month — among the lowest prices available in the US market for both medications. Its third-party tested pharmacy partnerships, 1,000+ physician network, overnight cold shipping, and flat-rate pricing create genuine value for price-sensitive patients who want clinician-supervised GLP-1 therapy without insurance. The FDA warning letter from February 2026, the 3-month commitment with punishing cancellation terms, inconsistent pricing across pages, and a 2.7/5 AllyRx user score are legitimate concerns that require honest attention. This review addresses all of it.

What Is NewSelf? Entity Definition and Platform Model

NewSelf GLP-1 is operated by NewSelf Limited LLC — a Wyoming registered technology company headquartered at 50 N Guild St Ste R, Sheridan WY 82801. NewSelf is not a pharmacy, not a medical clinic, and not a physician practice. It is a telehealth coordination platform: a technology layer that connects patients with an independent network of licensed US healthcare providers and partner 503A compounding pharmacies.

This organizational structure — common in telehealth — means the treating physician is legally independent from NewSelf, and the compounding pharmacy is also independent. NewSelf coordinates the flow: intake questionnaire → physician review → prescription → pharmacy fulfillment → shipping. When NewSelf's FDA warning letter cited misleading labeling, it was targeting NewSelf LLC's marketing and website content — not the compounding pharmacies themselves. This distinction matters for understanding the regulatory risk precisely.

The company serves all 50 US states through its physician network. Phone support: 1-855-606-5232. Email: support@newself.com. Patient portal provides secure messaging, refill management, and educational resources. NewSelf describes itself as the "last weight loss program you will ever need" — a bold claim that we'll evaluate against the available evidence throughout this review.

The Medications: What NewSelf Actually Dispenses

NewSelf offers two compounded GLP-1 medications, each enhanced with vitamins or amino acids. Understanding what these are — and what they aren't — is foundational to an honest assessment.

Semaglutide Plus⁺ ($99.97/month promotional)

Semaglutide Plus⁺ contains compounded semaglutide — the same active molecule as Ozempic and Wegovy — enhanced with either Cyanocobalamin (Vitamin B12) or Glycine. It is available in 0.25mg, 0.50mg, 1.0mg, 2mg, and 2.5mg dosage tiers, all at the same $99.97/month price. It is administered as a once-weekly subcutaneous injection. The B12 addition serves as nutritional support during GLP-1-driven caloric restriction — a legitimate clinical rationale, not a marketing gimmick. The Glycine option serves primarily as a pharmaceutical stabilizer.

Critical clarification: this is not Ozempic or Wegovy. It contains the same active ingredient (semaglutide) but is produced by a compounding pharmacy, not by Novo Nordisk. It is not FDA-approved. It has not undergone the FDA's new drug approval process for safety and efficacy. Read our detailed guide to the semaglutide + B12 blend.

Tirzepatide Plus⁺ ($144.49/month promotional)

Tirzepatide Plus⁺ contains compounded tirzepatide — the same active molecule as Mounjaro and Zepbound — enhanced with Pyridoxine (Vitamin B6) or Glycine. Available in 2.5mg through 15mg dosage tiers, all at $144.49/month. The dual GLP-1/GIP mechanism produces superior average weight loss to semaglutide: 22.5% average body weight reduction in the SURMOUNT-1 trial at the highest dose vs. 14.9% in STEP-1. Read our tirzepatide + B6 guide and our full semaglutide vs tirzepatide comparison.

Pricing Truth: The Inconsistency Problem

NewSelf's pricing is the most frequently cited source of confusion and concern in independent reviews — and for good reason. The company displays different prices across different pages of its own website, creating a legitimacy question even before any other issue is considered.

As of September 2026, the dedicated semaglutide product page shows $99.97/month. The main homepage at newself.com has at times shown $134.99/month. AllyRx's pricing audit records approximately $135/month. Some archived or older pages display $199/month or higher. For tirzepatide, the product page shows $144.49 while the homepage has shown $224.99 and AllyRx records ~$225/month.

Our guidance: confirm the exact recurring charge on your checkout screen before entering payment. Screenshot it. Email yourself confirmation. The page price is not a reliable indicator of what you'll be billed for months 2 and 3 of your commitment. This inconsistency is one of AllyRx's primary critiques: "The site does not present one authoritative, consistent price for each medication, so a screenshot or written confirmation of the final checkout terms is important." See our complete cost per month guide for the full breakdown.

The Commitment and Cancellation Terms: Read This Before Paying

NewSelf's cancellation and commitment structure is arguably the most consequential term for prospective patients — and the one most obscured by its marketing language. Here is the precise structure as documented by AllyRx's policy review and community reports:

Medication Quality and Pharmacy Standards

NewSelf's quality claims are among its strongest differentiators — and among the most important things to verify independently. NewSelf states that its partner 503A pharmacies conduct independent third-party laboratory testing of every medication batch, specifically:

• Potency testing: Confirms semaglutide or tirzepatide concentration is within the specified target range — not under-dosed (ineffective) or over-dosed (unsafe)
• Sterility testing: Confirms no microbial contamination (bacterial, fungal) in batch samples
• Endotoxicity testing (USP 85): Confirms absence of pyrogenic bacterial endotoxins that could cause fever, inflammation, or septic reactions

These are meaningful, substantive tests — not generic quality language. Weekly batch testing is more rigorous than many 503A pharmacies practice. The key caveat: NewSelf's marketing makes these claims about its pharmacy partners. The FDA warning letter targeted NewSelf's own marketing content. Patients should request certificates of analysis (CoA) from their dispensing pharmacy directly when medications arrive. See our full compounding safety guide for verification questions to ask.

The February 2026 FDA Warning Letter: Full Context

In February 2026, the Food and Drug Administration issued a formal warning letter to NewSelf LLC — cited by the FDA as NewSelf Limited dba NewSelf. The warning letter cited violations related to: misbranding of compounded semaglutide products (characterizing them in ways that misrepresented their regulatory status), false or misleading labeling claims about equivalence to brand-name products, and representations that implied FDA approval status that the compounded products do not have.

The FDA warning letter is a serious enforcement action. It is not, however, automatically equivalent to a product recall, facility shutdown, or finding of patient harm. It is a communication requiring NewSelf to respond with a remediation plan. NewSelf disputed the FDA's characterization and committed to response within the regulatory window. As of September 2026, the resolution of that response is not publicly confirmed in FDA's warning letter database.

What this means practically: NewSelf continues to operate. The medications continue to be dispensed. But the warning letter raises a legitimate question about whether NewSelf's communication to patients about what they're receiving has been fully accurate — a concern worth weighing when making a healthcare purchase decision. Read our dedicated FDA warning letter explainer.

The Clinical Process: How Doctor Review Actually Works

NewSelf's patient flow begins with an online health questionnaire covering medical history, current medications, weight and height, health goals, and relevant diagnoses. This intake is reviewed by a board-certified physician from NewSelf's independent provider network. The review is individualized — not automated eligibility scoring. If the physician determines GLP-1 therapy is clinically appropriate, a prescription is written. If not, a full refund is issued.

Patient reports of the consultation process are generally positive — multiple Trustpilot reviews describe the intake as "not rushed," "collaborative," and "thorough." The after-visit summary includes week-by-week dosing instructions and next steps. The initial prescription determines your starting dose; follow-up consultations (scheduled through the patient portal) allow dose adjustments as clinically indicated.

Key procedural detail: payment is charged at checkout — before the physician consultation. You are paying for the program including the consultation, and the refund structure covers the scenario where the doctor declines. Once the prescription is written and sent to the pharmacy, the financial transaction becomes largely one-directional. This front-loaded payment model is worth understanding clearly before checkout. See our step-by-step process guide.

Shipping, Delivery, and What to Expect

NewSelf advertises free overnight cold-chain shipping Monday through Thursday — no weekend shipping. Each shipment is a 3-month supply and includes: medication vials, 20 syringes, cold packs, a dosage bag with storage information, and 10 alcohol swabs. Approved prescriptions typically ship within 72 hours of pharmacy receipt. Total time from signup to first dose: 4–6 business days on average.

The cold-chain shipping is a meaningful differentiator — semaglutide and tirzepatide are temperature-sensitive medications. However, some negative patient reviews have reported receiving packages with compromised temperature control. One AllyRx review from May 2026 specifically described receiving a package that felt warm, citing medication at potentially unsafe temperatures. NewSelf's response to this customer cited a 21-day tolerance window at higher temperatures — a claim that conflicts with standard pharmaceutical stability guidance for GLP-1 medications. Semaglutide and tirzepatide stability above 86°F (30°C) is not reliably maintained. If your package arrives warm, assess it carefully and contact both NewSelf and your dispensing pharmacy. Report within 7 days — the policy window for shipping issues.

Review Analysis: What the Scores Really Mean

NewSelf's review landscape is genuinely split — and understanding why requires examining what each platform captures.

The Trustpilot 4.5 primarily reflects early-stage experience: onboarding, consultation quality, packaging, and initial medication effectiveness. Positive reviews consistently mention prompt doctor communication, professional packaging, and real appetite suppression onset by weeks 2–4. The 2.7/5 AllyRx user score reflects later-stage experience: billing, cancellation, and renewal. The gap between these two scores is not necessarily evidence of fraud — subscription services broadly tend to have this pattern. What it is: strong evidence that the experience after the first 30 days involves more friction than the marketing suggests.

From AllyRx's 12 reviews: 4 rated 4 stars (generally positive — consultation, app experience, follow-ups); 4 rated 3 stars (mixed — good consultation but app issues, limited analytics); 4 rated 1 star (negative — billing disputes, cancellation difficulty, medication effectiveness concerns, shipping temperature). See our full review analysis.

Is NewSelf Legitimate? Our Full Assessment

Legitimate by the structural definition: yes. NewSelf Limited LLC is a real registered company, with real licensed physicians, real 503A pharmacy partners, and real medication delivery. It is not a phantom website collecting credit card numbers. Patients do receive medication. Physicians do review intakes. The medications do contain active GLP-1 agents with documented efficacy.

Legitimate by the "trustworthy and transparent" definition: partially. The pricing inconsistency, the gap between "cancel anytime" marketing language and the formal 3-month commitment policy, the February 2026 FDA warning letter for misleading labeling, and community allegations about billing disputes all create a meaningful trust deficit. A company that operated with full transparency would show one consistent price across every page, make its cancellation terms prominently clear before checkout, and not receive FDA citations for misleading marketing claims.

Our assessment is that NewSelf occupies a legitimate-but-buyer-beware position. The medications are real, the prices are competitive, and many patients have positive experiences. But the operational and regulatory risks are real too — and they require active management: confirm checkout price, document cancellation terms, verify your dispensing pharmacy, and keep records. See our dedicated legitimacy analysis.

What NewSelf Won't Tell You (Information Gain Section)

The following information is either absent from, or contradicted by, NewSelf's official marketing — and represents genuine information gain beyond what you'd find on newself.com:

• The $99.97 price may not be your recurring charge. NewSelf's standard rate is $134.99 for semaglutide. The $99.97 is a promotional/affiliate-channel rate. Confirm at checkout what recurs on month 2 and month 3 — these may differ.
• Payment is charged before the consultation. You pay before a doctor approves your prescription. This is disclosed but underemphasized. The full refund-if-declined policy partially mitigates this, but the default state after checkout is "money transferred to NewSelf."
• The 3-month commitment creates asymmetric risk. You are obligated; NewSelf retains significant control over refund eligibility. Early cancellation can cost more than continuing.
• The dispensing pharmacy is not always the same. Different patients may have prescriptions filled by different 503A partners depending on state, availability, and capacity. Always confirm which specific pharmacy dispenses your medication and verify their licensure independently.
• Semaglutide shortage status changes compounding legality. Compounding is authorized during active drug shortages. As shortages resolve, the legal basis for compounding narrows. FDA's semaglutide shortage status has fluctuated in 2025–2026. Verify current status before enrolling.
• The FDA warning letter may affect future availability. Warning letters can precede further enforcement action. While NewSelf currently operates, its regulatory trajectory is uncertain. If compliance issues are not resolved satisfactorily, FDA can escalate.
• Reddit community concerns include possible rebrand allegations. Some community members allege NewSelf is connected to OhMyMeds, a prior questioned operator. This has not been confirmed by independent sources but appears in multiple threads with specificity. We mention it because prospective patients should know it exists in public discussion — not because we can confirm it.

Final Verdict: Who Should Use NewSelf

Strong fit: Price-sensitive adults who want compounded semaglutide or tirzepatide at the lowest available market rate, who can confirm the promotional price at checkout, who accept the 3-month commitment with full awareness of cancellation terms, who are comfortable with compounded (non-FDA-approved) medications, and who can tolerate the regulatory context of the February 2026 FDA warning letter. The value proposition at $99.97/month semaglutide or $144.49/month tirzepatide — with third-party testing, overnight shipping, and real clinical oversight — is genuinely compelling when those conditions are met.

Poor fit: Patients who want a transparent, consistent pricing experience; patients who may need to cancel before 3 months; patients who need FDA-approved brand-name medications; patients who are concerned about the FDA warning letter's implications; patients who need insurance billing; patients who want a platform with behavioral coaching or daily app engagement.